Mads Frederik Rasmussen

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

Arne Astrup, Stephan Rössner, Luc Van Gaal et al. · The Lancet · 2009 · 1.2K citations

Agriculture, Nutritional Sciences, Pharmacology +10

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Michael Horowitz, Anne Flint, Karen L. Jones et al. · Diabetes Research and Clinical Practice · 2012 · 176 citations

Medicine, Endocrinology, Pharmacology +15

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

Kohei Kaku, Mads Frederik Rasmussen, Tomoyuki Nishida et al. · Journal of Diabetes Investigation · 2011 · 46 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

Yutaka Seino, Mads Frederik Rasmussen, Tomoyuki Nishida et al. · Journal of Diabetes Investigation · 2011 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes

Yutaka Seino, Mads Frederik Rasmussen, Per Clauson et al. · Journal of Diabetes Investigation · 2012 · 17 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +16